Introduction {#Sec1}
============

Type 2 diabetes is a growing worldwide problem. One of the major risk factors for type 2 diabetes mellitus and cardiovascular disease is obesity \[[@CR1], [@CR2]\]. Because the incidence of obesity is increasing worldwide and has reached epidemic proportions in several countries \[[@CR3]\], the prevalence of obesity-related disorders, such as insulin resistance and hypertension, is rapidly increasing as well. It has been demonstrated that microvascular dysfunction affects both insulin-mediated glucose disposal \[[@CR4]--[@CR7]\] and peripheral vascular resistance \[[@CR8], [@CR9]\], contributing to insulin resistance and hypertension, respectively. We and others have shown that microvascular function is impaired in obesity \[[@CR6], [@CR10], [@CR11], [@CR12]•\]. Various bioactive compounds produced and released by adipose tissue (adipokines) influence vascular function and insulin sensitivity. In particular, signals from perivascular adipose tissue have been suggested to influence microvascular function contributing to obesity-associated insulin resistance and hypertension. In this review, we focus on the interactions between adipokines and microvascular function in relation to the development of insulin resistance, diabetes, and CVD.

Microcirculation and Perivascular Fat: Definition, Structure, and Function {#Sec2}
==========================================================================

Microcirculation {#Sec3}
----------------

The microcirculation, including arterioles, capillaries, and venules, can be defined on the basis of vessel diameter (\< 150 μm) or on the basis of the physiologic vasoconstrictor response to increased internal pressure \[[@CR13]\]. The most important functions of the microcirculation are 1) to regulate tissue perfusion and exchange surface area to ensure adequate delivery of nutrients, oxygen, and hormones; 2) to avoid large fluctuations in hydrostatic pressure at the capillary level; and 3) to regulate peripheral vascular resistance and thereby blood pressure \[[@CR13]\]. Optimal microvascular function is, therefore, essential for the regulation of whole body and tissue metabolism as well as blood pressure. Various autoregulatory mechanisms (systemic, regional, metabolic, and myogenic) determine microvascular function \[[@CR14], [@CR15]\]. In particular, endothelial cells (forming the inner lining of the microvasculature) play a central role in translating circulating factors (eg, hormones, fatty acids, nutrients) to vasodilator (nitric oxide \[NO\], endothelium-derived hyperpolarization factor \[EDHF\], prostaglandins \[PGI2/PGE2\]) and vasoconstrictor (eg, endothelin-1 \[ET-1\]) factors \[[@CR16]\].

Perivascular Adipose Tissue {#Sec4}
---------------------------

Perivascular fat, or perivascular adipose tissue (PVAT), consists of adipocytes, fibroblasts, stem cells, mast cells, and nerves \[[@CR17]--[@CR19]\]. It can be found throughout the body, around most arteries and veins with a diameter \> 50 μm. Specific locations where PVAT has been studied are around the coronary arteries (epicardial adipose tissue), the aorta (periaortic adipose tissue), and in the microcirculation of the mesentery and adipose tissue \[[@CR20], [@CR21], [@CR22], [@CR23], [@CR24], [@CR25]••\]. In muscle, regulation of local perfusion by perivascular adipose tissue has been proposed \[[@CR23]\]. Aortic perivascular adipose tissue expands in situations of nutrient excess and obesity \[[@CR26]\]. In the heart, PVAT volume has been found to correlate with the amount of intra-abdominal fat \[[@CR26], [@CR27]••\]. The mechanisms causing expansion of perivascular adipose tissue are still under investigation, but likely involve differentiation of resident mesenchymal stem cells and preadipocytes, as well as infiltration and differentiation of stem cells from bone marrow. PVAT, at different locations, has been shown to secrete a wide variety of adipose tissue-derived hormones (adipokines) and other substances, including hormones, cytokines, chemokines, fatty acids, components of the renin-angiotensin system and oxygen radicals \[[@CR20], [@CR28]\]. However, the rate of excretion of various adipokines may vary between PVAT at different sites in the vascular tree and between PVAT and other adipose tissue depots \[[@CR25]••, [@CR29]••\]. Adipokines such as fatty acids, tumour necrosis factor α, (TNFα) and adiponectin have been shown to affect insulin sensitivity and also inflammatory responses, appetite, atherosclerosis, and hemostasis \[[@CR30]\].

Microvascular Dysfunction in Insulin Resistance, Obesity, and Hypertension {#Sec5}
==========================================================================

Microvascular dysfunction is not only characteristic for insulin resistance and hypertension \[[@CR31]\], but may be involved in the pathogenesis and progression of these conditions as well, as microvascular changes have been demonstrated to occur very early, even before clinical manifestation \[[@CR9], [@CR32]--[@CR34]\]. Alternatively, by affecting both peripheral resistance and glucose metabolism, microvascular changes that result from hypertension could also predispose to insulin resistance and vice versa.

Insulin Resistance {#Sec6}
------------------

The classic definition of insulin resistance is a decreased sensitivity and/or responsiveness to metabolic actions of insulin that promote glucose disposal. A major action of insulin in skeletal muscle is translocation of the glucose transporter (GLUT-4) to the plasma membrane and subsequent activation of downstream pathways of glucose metabolism \[[@CR35]\]. A necessary requirement for this process is delivery of insulin and glucose to tissue interstitium. This delivery is regulated to a great extent by insulin itself via direct effects on vascular function \[[@CR35], [@CR36]•\].

Over 20 years ago, several studies demonstrated direct vasodilator effects of insulin in skeletal muscle-resistance vessels, thereby increasing muscle blood flow \[[@CR4], [@CR37]--[@CR39]\]. Subsequently, in a wide range of insulin-resistant states (eg, hypertension, obesity, type 2 diabetes), this vasodilator effect of insulin was shown to be impaired. This led to the hypothesis that the vasodilator and metabolic actions of insulin are functionally coupled \[[@CR35], [@CR40]\], although the time kinetics and dosages of insulin required to increase total muscle blood flow appear to be different from those for insulin-induced glucose uptake \[[@CR41], [@CR42]\]. This apparent dissociation in the effects of insulin on muscle blood flow and glucose uptake resulted in a shift of focus from insulin's actions in the macrocirculation to actions in the microcirculation. The groups of Clark and Barrett then introduced the concept that distribution of blood flow within the microcirculation, independent of changes in total muscle flow, may be important for insulin-mediated glucose metabolism \[[@CR4], [@CR43], [@CR44]\]. They showed that insulin-induced changes in muscle microvascular perfusion were consistent with capillary recruitment \[[@CR42], [@CR45]--[@CR47]\]. By vasodilation of precapillary arterioles connected to nutritive capillary networks, insulin induces capillary recruitment, resulting in a redistribution of blood flow from putatively non-nutritive transit and/or connective tissue microvessels to nutritive capillaries \[[@CR40], [@CR48], [@CR49]\]. This capillary recruitment was shown to be associated with changes in muscle glucose uptake independently of changes in total blood flow, to require lower insulin concentrations than necessary for changes in total blood flow, and to approximate the time course for insulin-mediated glucose uptake in skeletal muscle (ie, 5--10 min) \[[@CR42], [@CR50], [@CR51]\]. Approximately 40% of insulin-stimulated muscle glucose uptake can be attributed to this capillary recruitment \[[@CR47], [@CR51], [@CR52]\].

These vasodilator actions of insulin involve the endothelial insulin receptor, insulin receptor substrate 1 and 2 (IRS1 and IRS2), PI3-kinase, phosphoinositide-dependent kinase 1 (PDK-1), and protein kinase B (Akt) \[[@CR35], [@CR36]•\]. Insulin-induced stimulation of Akt directly increases endothelial nitric oxide (NO) production via endothelial nitric oxide synthase (eNOS) \[[@CR35], [@CR53]\]. The metabolic action of insulin to stimulate glucose uptake in skeletal muscle and adipose tissue is mediated through stimulation of similar PI3-kinase--dependent signaling pathways. Besides vasodilator actions, insulin has vasoconstrictor effects as well. These vasoconstrictor effects are mainly mediated by the vasoconstrictor peptide endothelin-1 (ET-1) \[[@CR35]\]. ET-1 is produced in the vascular endothelium through stimulation of the intracellular mitogen-active protein kinase (MAPK) signaling pathway and the extracellular signal-regulated kinase-1/2 (ERK1/2) \[[@CR54]\]. Thus, insulin has opposing endothelium-derived vasodilator and vasoconstrictor effects, with the net effect being dependent on the balance between these two \[[@CR12]•\]. Normally, the net result is vasodilation.

Microcirculation in Obesity and Insulin Resistance {#Sec7}
--------------------------------------------------

Most studies examining microvascular function in the insulin-resistant state have been performed in obese individuals \[[@CR55]\]. These studies have demonstrated that obese insulin-resistant individuals are characterized by several impairments in the microvasculature. The presence of endothelial dysfunction has been established by blunted NO-mediated vasodilator responses in skin and resistance arterioles to classic endothelium-dependent vasodilators \[[@CR11], [@CR56]--[@CR61]\] and impaired capillary recruitment to reactive hyperemia \[[@CR11], [@CR62]\]. In support of a causal role for obesity in the pathogenesis of endothelial dysfunction, weight loss has been found to improve endothelial function \[[@CR63]\]. At the same time, obese insulin-resistant patients have elevated plasma ET-1 levels \[[@CR64]\]. A key feature of insulin resistance is that it is characterized by specific impairment in PI3K-dependent signaling pathways, whereas insulin's signaling through the MAPK pathways remains intact \[[@CR36]•, [@CR65]--[@CR67]\], resulting in vasoconstriction. Indeed, several studies have demonstrated impaired vasodilation and capillary recruitment in response to insulin in skin and skeletal muscle of insulin-resistant individuals \[[@CR11], [@CR68], [@CR69], [@CR70]•, [@CR71], [@CR72]\]. As metabolic insulin resistance is usually accompanied by compensatory hyperinsulinemia (to maintain euglycemia), this hyperinsulinemia in the vasculature will stimulate unaffected MAPK-dependent pathways, leading to decreased production of NO and increased secretion of ET-1 \[[@CR54], [@CR66], [@CR73]--[@CR75]\]. As a consequence, vasoconstriction of resistance arteries and terminal arterioles occurs, leading to impaired regulation of muscle perfusion, glucose uptake, and blood pressure \[[@CR13]\]. Recently, resistance to insulin's effects on vascular endothelium has indeed been shown to control insulin sensitivity in mice \[[@CR36]•\].

Microcirculation in Hypertension {#Sec8}
--------------------------------

Hypertension per se is also characterized by functional as well as structural changes in the microcirculation \[[@CR31]\], including impaired vasoregulation \[[@CR76]\], increases in wall-to-lumen ratio of small arteries \[[@CR31], [@CR77]\], and structural and functional capillary rarefaction \[[@CR5], [@CR13], [@CR78], [@CR79]\]. The presence of endothelial dysfunction in hypertension has been established by blunted vasodilator responses and capillary recruitment to classic endothelium-dependent vasodilators (eg, acetylcholine) and mechanical stimulation (shear stress) \[[@CR5], [@CR80]\]. Recent studies also demonstrated impaired insulin-mediated NO-dependent vasodilation in different animal models of hypertension \[[@CR81]--[@CR83]\]. In addition to the decrease in NO availability, hypertension is characterized by a parallel increase in the release of the endothelium-derived contracting factor ET-1 and in the vasoconstrictor angiotensin II (Ang II) \[[@CR76], [@CR84]\].

Whereas it has been known for many years that these microvascular alterations can be secondary to sustained elevation of blood pressure \[[@CR85], [@CR86]\], there is also evidence that microvascular changes can be a cause rather than a consequence of hypertension \[[@CR8], [@CR9], [@CR87]\]. Microvascular abnormalities occur early during development of hypertension in spontaneously hypertensive rats (SHR) \[[@CR81], [@CR88]\], and prevention of oxidative stress by antioxidant treatment not only prevents rarefaction \[[@CR88]\] but also prevents the age-related development of hypertension \[[@CR89]\]. Furthermore, capillary rarefaction, similar to the magnitude seen in patients with established hypertension, can already be demonstrated in individuals with borderline hypertension \[[@CR8]\] and in individuals with a familial predisposition to hypertension, even if they themselves are normotensive \[[@CR9], [@CR32]\]. Thus, it seems likely that microvascular abnormalities can both result from and contribute to hypertension, and a continuing cycle may exist in which the microcirculation maintains or even amplifies an initial increase in blood pressure. However, microvascular dysfunction (including vascular insulin resistance) due to hypertension may also directly reduce the access of insulin and glucose to skeletal muscle, resulting in reduced insulin sensitivity.

To summarize, there are several arguments for a causal role of microvascular insulin resistance and dysfunction in metabolic insulin resistance and hypertension (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR90]\]. Subsequently, the hyperglycemia and hyperinsulinemia that evolve with metabolic insulin resistance can further impair endothelial function \[[@CR91], [@CR92]\] and consequently glucose disposal and blood pressure. Hence, it is possible to envision a vicious circle of progressive microvascular dysfunction that contributes to and is exacerbated by worsening metabolic insulin resistance and hypertension.Fig. 1The postulated pathophysiologic framework underlying the hypothesis that microvascular dysfunction links hypertension and insulin resistance. ACE---angiotensin-converting enzyme; ARB---angiotensin II receptor blocker; RAS---renin-angiotensin system; TNFα---tumor necrosis factor α. (*Adapted from* Jonk \[[@CR90]\].)

Adipose Tissue and Microvascular Dysfunction {#Sec9}
============================================

The fact that there are associations between measures of adiposity and microvascular function \[[@CR93]\] indicates the existence of signaling pathways between adipose tissue and the microcirculation. A large number of recent studies have proven that adipose tissue functions as a highly active endocrine organ. Adipose tissues secrete a variety of bioactive substances called adipokines. In obesity, it has been shown that there is an enhanced production of several adipokines (eg, free fatty acids \[FFA\], angiotensinogen, leptin, resistin, and several inflammatory cytokines) \[[@CR63], [@CR94]--[@CR97]\], whereas the production of adiponectin, an anti-inflammatory adipokine, is reduced \[[@CR98]\]. In recent years, perivascular adipose tissue has been identified as a source of adipokines, which are summarized in Table [1](#Tab1){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}. The rate of excretion of various adipokines differs between perivascular adipose tissue and other adipose tissue depots, and may vary between PVAT at different sites in the vascular tree \[[@CR25]••, [@CR29]••\]. Here we discuss some major adipokines and their effects on (micro)vascular function.Table 1Products of perivascular adipose tissue involved in regulation of vascular functionReferencesCytokines TNFα\[[@CR20], [@CR27]••\] IL-1β\[[@CR20], [@CR27], [@CR27]••\] IL-6\[[@CR7], [@CR19], [@CR20]\]Chemokines MCP-1\[[@CR20], [@CR111]\] IL-8\[[@CR111]\] MIP-1α\[[@CR29]••\]Hormones and fatty acids Leptin\[[@CR29]••, [@CR110]\] Adiponectin\[[@CR25]•, [@CR29]••\], \[[@CR103]--[@CR105]\] FABP4\[[@CR29]••\] FFA\[[@CR110]\]Vasoactive agents Angiotensinogen\[[@CR116]\] Ang II\[[@CR116], [@CR130]\] Ang (1--7)\[[@CR115]\] ROS\[[@CR110], [@CR113], [@CR121], [@CR125]\] H~2~S\[[@CR128]\]Ang II angiotensin II; Ang (1--7) angiotensin (1--7); FABP4 fatty acid-binding protein 4; H~2~S hydrogen sulphate; FFA free fatty acids; IL interleukin-; MCP-1 monocyte chemoattractant protein-1; MIP-1α macrophage inflammatory protein-1α; ROS reactive oxygen species; TNFα tumor necrosis factor α

Adiponectin {#Sec10}
-----------

Adiponectin is an abundant protein in the human circulation that has been shown to be inversely associated with risk for type 2 diabetes, to increase insulin sensitivity, and to improve vascular function \[[@CR99], [@CR100]\]. Adiponectin expression is limited to adipocytes, but paradoxically, its levels are decreased in obesity. This defect has been proposed to be caused by TNFα and interleukin-6 (IL-6), as well as other inflammatory mediators \[[@CR30], [@CR101]\]. Adiponectin itself can reduce production of proinflammatory cytokines, and favorably affects insulin-signaling pathways \[[@CR102]\].

It has been shown that PVAT in the coronary circulation \[[@CR103]\] and in adipose tissue produces adiponectin \[[@CR25]••\]. In subjects with coronary artery disease, production of adiponectin is reduced in epicardial adipose tissue \[[@CR104]\]. In mice, a high-fat diet was found to decrease adiponectin secretion from PVAT \[[@CR29]••\]. The secretion of adiponectin by differentiated coronary perivascular adipocytes was much lower when compared to subcutaneous and perirenal adipocytes, suggesting that PVAT would have a more inflammatory profile than other fat depots \[[@CR29]••\]. Conversely, another study has reported similar concentrations of adiponectin in PVAT, and subcutaneous and abdominal visceral adipose tissue \[[@CR105]\]. However, in the latter study, adiponectin was measured in homogenates of the adipose depots, and synthesis does not necessarily equal secretion.

Leptin {#Sec11}
------

Leptin, the product of the ob gene discovered in 1994, is one of the best-known adipokines. Deficiency of leptin activity leads to severe obesity, insulin resistance, and vascular dysfunction in mice and rats \[[@CR7], [@CR106]\], showing that leptin controls metabolism and vascular function. Leptin has been shown to increase NO production in the presence of insulin \[[@CR107]\]. In humans, leptin deficiency is associated with hyperphagia, obesity, and insulin resistance \[[@CR108]\], although circulating levels of leptin are generally increased in obesity. Recent data have suggested that obesity is a leptin resistant state \[[@CR109]\]. Perivascular adipose tissue expresses leptin, although to a somewhat lower extent than subcutaneous and perirenal adipose tissue, and leptin secretion increases during diet-induced obesity \[[@CR29]••, [@CR110]\].

Cytokines and Chemokines {#Sec12}
------------------------

A substantial number of studies have shown that PVAT is a source of predominantly proinflammatory, cytokines and chemokines \[[@CR20], [@CR111], [@CR112]\]. Mazurek et al. found that epicardial PVAT from 42 patients who underwent elective coronary artery bypass graft (CABG) surgery excreted higher amounts of IL-1β, IL-6, IL-6sR, and TNFα than subcutaneous adipose tissue from these same patients \[[@CR20]\]. In another study, IL-6 and IL-8 excretion in differentiated perivascular adipocytes was higher than in subcutaneous and perirenal fat, as well as MCP-1 release \[[@CR29]••\]. Importantly, the amount of cytokines excreted by PVAT did not correlate with plasma cytokine concentrations. These findings illustrate the importance of adipose tissue location and that systemic concentrations of adipokines may not be representative of local concentrations in tissues. Also, the inflammatory properties of epicardial adipose tissue were independent of obesity \[[@CR20]\]. Aside from cytokines, PVAT is also a source of chemokines such as IL-8, MCP-1, and RANTES \[[@CR111], [@CR113]\]. These have been implicated in the initiation of vessel wall inflammation and concomitant production of cytokines.

Adventitia-Derived Relaxing Factor {#Sec13}
----------------------------------

Perivascular adipose tissue around the aorta and mesenteric arteries of rats has been shown to exert a direct relaxing effect on vascular smooth muscle, mediated by one or more adventitia-derived relaxing factors (ADRFs) \[[@CR22], [@CR114]\]. One of these ADRFs has been identified in rats as angiotensin 1--7 \[[@CR115]\]. In humans, adiponectin is a prominent ADRF, and the role of angiotensin 1--7 has not been proven.

Renin-Angiotensin System {#Sec14}
------------------------

Perivascular adipose tissue has been shown to express all components of the renin-angiotensin system except renin \[[@CR116]\], and this has been implicated in the pathogenesis of hypertension. The production of angiotensin II by mesenteric adipose tissue was found to be higher than that in periaortic adipose tissue, showing regional differences in this system \[[@CR116]\]. Interestingly, angiotensin II type-1 (AT1) receptor blockade (ARB) improves insulin sensitivity, which seems to be related to effects on adipose tissue \[[@CR117], [@CR118]\]. Although acute angiotensin II infusion in healthy subjects reduces capillary density and acute ARB treatment in hypertensive subjects stimulates capillary density, these acute changes in capillary densities are not directly coupled to subsequent changes in insulin-mediated glucose uptake \[[@CR119], [@CR120]\].

Reactive Oxygen Species {#Sec15}
-----------------------

Production of reactive oxygen species by PVAT has primarily been found in the larger arteries of rats and mice. ROS production in PVAT is produced by NADPH oxidase in immune cells \[[@CR113], [@CR121]\], can be increased by angiotensin II \[[@CR122]\], and has been found to be increased in experimental obesity \[[@CR121]\].

Perivascular Adipose Tissue as a Regulator of Microvascular Function {#Sec16}
====================================================================

Accumulating evidence suggests that the products of PVAT contribute to regulation of (micro)vascular function and, subsequently as a consequence, may influence organ function and even insulin sensitivity \[[@CR23], [@CR40]\]. The hypothesis that perivascular adipose tissue controls glucose metabolism is supported by strong statistical relationships between ectopic fat and insulin sensitivity, the fact that vascular function contributes to regulation of insulin sensitivity \[[@CR36]•\], and by recent evidence that PVAT controls vascular tone \[[@CR25]••\]. At present, the role of PVAT in the pathogenesis of diabetes and the associated cardiovascular disease is still being defined.

PVAT and Endothelium-Dependent Vasodilation {#Sec17}
-------------------------------------------

Endothelium is an important modifier of vascular tone, and recent evidence suggests PVAT alters the balance between endothelium-dependent vasodilator and vasoconstrictor substances such as NO and endothelin-1 \[[@CR123]\]. This is illustrated by studies showing that the amount of PVAT surrounding the brachial artery is negatively associated with post-ischemic increases in forearm blood flow. In contrast, increased PVAT around the brachial artery does not associate with flow-mediated dilatation of the brachial artery itself \[[@CR27]••\], suggesting that PVAT is able to affect microvascular function at distal sites ("vasocrine" signaling) and that the effects of PVAT are vessel specific. Anti-contractile properties of PVAT are not only seen in large arteries but also in the microcirculation of the mesentery and adipose tissue \[[@CR25]••\].

In subcutaneous gluteal fat of healthy lean subjects, anti-contractile properties of PVAT around microvessels have also been demonstrated \[[@CR25]••\]. The anti-contractile properties of PVAT were shown to be mediated by adiponectin and were abrogated in patients with metabolic syndrome, suggesting functional differences between PVAT from lean subjects and subjects with metabolic syndrome. Moreover, hypoxia, which is known to decrease adiponectin production, attenuates the anti-contractile properties of PVAT \[[@CR25]••, [@CR124]\].

PVAT has also been shown to attenuate endothelium-dependent vasodilatation in pathologic situations, and this effect may be mediated by leptin and reactive oxygen species. Epicardial PVAT from swine with a diet-induced metabolic syndrome excretes more leptin than epicardial perivascular adipose tissue in lean swine, and the increased production of leptin attenuates endothelium-dependent vasodilation by activating protein kinase C \[[@CR110]\]. In New Zealand obese mice with metabolic syndrome, a role for PVAT-derived reactive oxygen species in attenuation of endothelium-dependent vasodilatation has been demonstrated \[[@CR121]\].

Healthy PVAT enhances endothelium-dependent vasodilation, probably through adiponectin or leptin. Contrarily, leptin may also enhance vascular constriction. However, in pathologic conditions these properties of PVAT seem to be attenuated. The exact mechanisms through which PVAT modulates (micro)vascular tone remain to be investigated.

Direct Effects of PVAT on Smooth Muscle Tone {#Sec18}
--------------------------------------------

Aside from interaction with vascular endothelium, perivascular adipose tissue is also able to act directly on vascular smooth muscle to determine vascular tone and diameter via release of both vasodilator and vasoconstrictor substances.

Vasorelaxation by perivascular adipose tissue of the aorta was the first vasoactive effect reported for PVAT, leading to the proposed release of an ADRF (or perivascular adipose tissue derived relaxing factor \[PVRF\]) \[[@CR125]\]. In spontaneously hypertensive rats \[[@CR126]\] and insulin-resistant fructose-fed rats \[[@CR127]\], the relaxing effect of PVAT on mesenteric arteries was found to be impaired. At present, the nature of the ADRFs is not fully clear, although angiotensin 1--7 \[[@CR115]\], adiponectin \[[@CR25]••\], and hydrogen sulfide \[[@CR128]\] have been mentioned as ADRFs. Interestingly, adiponectin receptor blockade did not inhibit the relaxing effect of PVAT in the rat mesenteric bed \[[@CR129]\], in contrast to the PVAT effect in human adipose tissue. This indicates that ADRFs may be different between various tissues, species, or both.

PVAT is also able to enhance vasoconstrictor responses, the mediator of which is likely angiotensin II. In mesenteric arteries, PVAT was shown to enhance constriction induced by nerve stimulation, an effect mediated by angiotensin II \[[@CR130]\].

In summary, PVAT interacts with smooth muscle tone via direct as well as indirect mechanisms, which are likely tissue specific. The net effect of PVAT can either be vasoconstrictor or vasodilator, and it is modulated by obesity and hypertension.

PVAT and Insulin Sensitivity {#Sec19}
----------------------------

As mentioned above, vascular function, and especially microvascular blood volume in muscle, is related to insulin sensitivity. Because obesity is associated with insulin resistance, reduction of microvascular blood volume, and altered properties of PVAT, we have proposed that PVAT causes microvascular dysfunction and insulin resistance in obesity \[[@CR23], [@CR131]\]. Although there are at present no studies that prospectively link PVAT to diabetes, a number of studies provide indirect evidence for this hypothesis. First, accumulation of ectopic adipose tissue, especially within muscles, strongly relates to local insulin sensitivity. The amount of PVAT surrounding the brachial artery \[[@CR27]••\] and adipose tissue between muscles (intermuscular adipose tissue \[IMAT\]) \[[@CR132]\] are inversely related to insulin sensitivity. Even though IMAT accounts for only 3% of total thigh adipose tissue, it has the strongest correlation with insulin sensitivity in obese subjects and subjects with type 2 diabetes mellitus \[[@CR133]\]. Second, aside from intermuscular adipose tissue and PVAT around the femoral artery, we have found accumulation of PVAT around the arterioles that regulate muscle perfusion \[[@CR131]\]. By regulating endothelium-dependent vasodilatation, insulin-mediated vasoreactivity, and muscle perfusion, PVAT may control muscle glucose uptake and, hence, determine risk of future type 2 diabetes.

Taken together, these data support the hypothesis that PVAT is one of the causes of insulin resistance. The strongest data for or against this hypothesis will likely come from PVAT-specific transgenic mouse models, but at present such models do not exist.

Conclusions {#Sec20}
===========

There is solid evidence for an important role for the microcirculation as a possible link between the cardiometabolic risk factors insulin resistance and hypertension, conditions that may further develop into diabetes with subsequent cardiovascular disease. Obesity is an important risk factor for insulin resistance and hypertension, and it is associated with several impairments in the microcirculation, including impaired endothelial function and rarefaction. Recent studies have shown that PVAT relates to endothelium-dependent vasodilatation and inflammation by secreting a variety of substances that affect vascular tone and infiltration of inflammatory cells (Fig. [2](#Fig2){ref-type="fig"}). However, the mechanisms controlling the quantity of PVAT and its secretion of adipokines remain to be determined. Because PVAT is located within insulin target tissues, controls (micro)vascular function, and is associated with insulin resistance, it may well contribute to the pathogenesis of type 2 diabetes and cardiovascular disease.Fig. 2Products of perivascular adipose tissue involved in regulation of (micro)vascular function. Depicted is perivascular adipose tissue in a biopsy taken from the quadriceps muscle of a type 2 diabetic patient. The *black arrow* indicates a microvessel. ADRF---adventitia-derived relaxing factor; Ang II---angiotensin II; Ang (1--7)---angiotensin (1--7); FABP4---fatty acid-binding protein 4; H~2~S---hydrogen sulphate; IL---interleukin-; MCP-1---monocyte chemoattractant protein-1; MIP-1α---macrophage inflammatory protein-1α; ROS---reactive oxygen species; TNFα*---*tumor necrosis factor α
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